Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | TCF4 | P15884 | 2/20 | 0.54 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.54 |
| ▸ | EGFR | P00533 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | KDR | P35968 | 1/20 | 0.54 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17331311 | 0.91 | KDM1A (0.70) | KDM1AMAOAMEN1KMT2ALMNA | |
| SCHEMBL17331331 | 0.90 | LMNA (0.60) | KDM1AMAOAMEN1KMT2ALMNA | |
| SCHEMBL17331308 | 0.87 | KMT2A (0.50) | KDM1AMAOAMEN1KMT2ALMNA | |
| SCHEMBL17347406 | 0.84 | LMNA (0.74) | KDM1AMAOAMEN1KMT2ALMNA | |
| SCHEMBL17347484 | 0.84 | ALDH1A1 (0.63) | MEN1KMT2ALMNAHPGDMAPT | |
| SCHEMBL17347396 | 0.82 | ALDH1A1 (0.58) | MEN1KMT2AHPGDBDKRB1MAPT | |
| SCHEMBL8367822 | 0.82 | KDM1A (0.60) | KDM1AMAOAMEN1KMT2ALMNA | |
| SCHEMBL8369354 | 0.80 | TCF4 (0.80) | MEN1KMT2ALMNAHDAC2HDAC8 | |
| SCHEMBL8699498 | 0.80 | KDM1A (0.63) | KDM1AMAOAMEN1KMT2ALMNA | |
| SCHEMBL17331333 | 0.80 | BDKRB1 (0.51) | MEN1KMT2ABDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023076404-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ARIA PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| WO-2023076404-A1 | METHODS FOR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | ARIA PHARMACEUTICALS, INC. (US) | 2023-05-04 | — | — | WO | disclosed |
| US-10004751-B2 | Compositions and methods for treating Dengue virus infection | THE J. DAVID GLADSTONE INSTITUTES (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170209460-A1 | COMPOSITIONS AND METHODS FOR TREATING DENGUE VIRUS INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-07-27 | — | — | US | disclosed |
| US-9701627-B2 | LRRK2 GTP binding inhibitors for treatment of Parkinson's disease and neuroinflammatory disorders | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-11 | — | — | US | disclosed |
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | UNIVERSITY OF MARYLAND, BALTIMORE | 2015-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150361038-A1 | LRRK2 GTP BINDING INHIBITORS FOR TREATMENT OF PARKINSON'S DISEASE AND NEUROINFLAMMATORY DISORDERS | LRRK2, PARK7, SNCA | KDM1A 4394/4885MAOA 3579/4885MEN1 4396/4885 |
| US-10004751-B2 | Compositions and methods for treating Dengue virus infection | C5, HAVCR2, MAVS | KDM1A 1987/4885MAOA 1411/4885MEN1 3171/4885 |
| US-20170209460-A1 | COMPOSITIONS AND METHODS FOR TREATING DENGUE VIRUS INFECTION | C5, HAVCR2, MAVS | KDM1A 1987/4885MAOA 1411/4885MEN1 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.